Protalix BioTherapeutics Treats First Gaucher Patient in Phase I Study With PRX-112, an Orally-Administered Enzyme Treatment of Gaucher Disease

[at noodls] – CARMIEL, Israel, April 2, 2013 (GLOBE NEWSWIRE) — Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX), announced today that the first patient has been treated in the Company’s phase I clinical trial … more

View todays social media effects on PLX

View the latest stocks trending across Twitter. Click to view dashboard

See who Protalix is hiring next, click here to view